PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Pathology and Translational Medicine10.4132/jptm.2020.05.122020544310-317Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in KoreansSue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Junghttp://www.jpatholtm.org/upload/pdf/jptm-2020-05-12.pdf, http://www.jpatholtm.org/journal/view.php?doi=10.4132/jptm.2020.05.12, http://www.jpatholtm.org/upload/pdf/jptm-2020-05-12.pdf
PLOS ONE10.1371/journal.pone.01533192016114e0153319BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese PatientsJian Sun, Jing Zhang, Junliang Lu, Jie Gao, Xinyu Ren, Lianghong Teng, Huanli Duan, Yansong Lin, Xiaoyi Li, Bo Zhang, Zhiyong Lianghttp://dx.plos.org/10.1371/journal.pone.0153319
Diagnostic Pathology10.1186/s13000-019-0849-62019141Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest ChinaMeiling Huang, Changjiao Yan, Jingjing Xiao, Ting Wang, Rui Linghttp://link.springer.com/content/pdf/10.1186/s13000-019-0849-6.pdf, http://link.springer.com/article/10.1186/s13000-019-0849-6/fulltext.html, http://link.springer.com/content/pdf/10.1186/s13000-019-0849-6.pdf
The Laryngoscope10.1002/lary.2466820141249E389-E393BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinomaDaniel J. Givens, Luke O. Buchmann, Archana M. Agarwal, Johannes F. Grimmer, Jason P. Hunthttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Flary.24668, https://onlinelibrary.wiley.com/doi/full/10.1002/lary.24668
European Journal of Cancer10.1016/s0959-8049(16)31616-1201551S5832879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinomaK. Wang, S. Ganesan, A. Johnson, J.P. Sharman, A. Chachoua, K. Hirshfield, J. Aisner, R. Yelensky, D. Lipson, J.A. Elvin, J. Chmielecki, P.J. Stephens, J.S. Ross, V.A. Miller, S.H.I. Ou, S.M. Alihttps://api.elsevier.com/content/article/PII:S0959804916316161?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804916316161?httpAccept=text/plain
Cancer Management and Research10.2147/cmar.s1595832018Volume 101005-1013Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasisHaoyu Ren, Yifan Shen, Daixing Hu, Wei He, Jing Zhou, Yijia Cao, Yu Mao, Yi Dou, Wei Xiong, Qi Xiao, Yuhong Zhang, Xinliang Suhttps://www.dovepress.com/getfile.php?fileID=41875, https://www.dovepress.com/getfile.php?fileID=41875
Acta Medica Bulgarica10.2478/amb-2021-000120214811-8Clinicopathological Significance of BRAF (V600E), NRAS (Q61K) and TERT (C228T, C250T and SNP Rs2853669) Mutations in Bulgarian Papillary Thyroid Carcinoma PatientsK. Vidinov, R. Dodova, P. Mitev, A. Mitkova, I. Dimitrova, A. Shinkov, R. Ivanova, V. Mitev, R. Kanevahttps://www.sciendo.com/pdf/10.2478/amb-2021-0001
Clinical Thyroidology10.1089/ct.2016;28.150-1522016285150-152Does BRAF V600E, BRAF-wt, or BRAF Pseudogene Expression Predict Aggressiveness of Papillary Thyroid Carcinoma?Charles H. Emersonhttp://www.liebertpub.com/doi/full-xml/10.1089/ct.2016%3B28.150-152, http://www.liebertpub.com/doi/pdf/10.1089/ct.2016%3B28.150-152
APMIS10.1111/j.1600-0463.2011.02844.x20111205380-386BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patientsHANNA PELTTARI, CAMILLA SCHALIN-JÄNTTI, JOHANNA AROLA, ELIISA LÖYTTYNIEMI, SAKARI KNUUTILA, MATTI J. VÄLIMÄKIhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0463.2011.02844.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0463.2011.02844.x/fullpdf
International Journal of Cancer10.1002/ijc.28976201413751001-1011Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaGreta Gandolfi, Valentina Sancisi, Simonetta Piana, Alessia Ciarrocchihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fijc.28976